Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:487991rdf:typepubmed:Citationlld:pubmed
pubmed-article:487991lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C0033975lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C0018546lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C1511726lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C0201734lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C1522609lld:lifeskim
pubmed-article:487991lifeskim:mentionsumls-concept:C1554112lld:lifeskim
pubmed-article:487991pubmed:issue3lld:pubmed
pubmed-article:487991pubmed:dateCreated1979-12-29lld:pubmed
pubmed-article:487991pubmed:abstractTextPharmacokinetic data of psychotropic drugs should allow a better understanding of therapeutic results and side effects. The different factors influencing liberation, absorption, protein binding, distribution, metabolism and excretion are reviewed. Then, the principal pharmacokinetic data of haloperidol are exposed with a special emphasis on the lack of information about the correlations between plasma levels and clinical effects. The role of pharmacokinetic informations in the interpretation of responses to treatment is detailed, wishing that the monitoring of haloperidol plasma levels will be more developped in a next future.lld:pubmed
pubmed-article:487991pubmed:languagefrelld:pubmed
pubmed-article:487991pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:487991pubmed:citationSubsetIMlld:pubmed
pubmed-article:487991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:487991pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:487991pubmed:statusMEDLINElld:pubmed
pubmed-article:487991pubmed:issn0013-7006lld:pubmed
pubmed-article:487991pubmed:authorpubmed-author:DenikerPPlld:pubmed
pubmed-article:487991pubmed:authorpubmed-author:LôoHHlld:pubmed
pubmed-article:487991pubmed:authorpubmed-author:ZarifianEElld:pubmed
pubmed-article:487991pubmed:authorpubmed-author:CucheHHlld:pubmed
pubmed-article:487991pubmed:authorpubmed-author:CottereauM...lld:pubmed
pubmed-article:487991pubmed:issnTypePrintlld:pubmed
pubmed-article:487991pubmed:volume5lld:pubmed
pubmed-article:487991pubmed:ownerNLMlld:pubmed
pubmed-article:487991pubmed:authorsCompleteYlld:pubmed
pubmed-article:487991pubmed:pagination197-203lld:pubmed
pubmed-article:487991pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-H...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-P...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-K...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-H...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-I...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-T...lld:pubmed
pubmed-article:487991pubmed:meshHeadingpubmed-meshheading:487991-P...lld:pubmed
pubmed-article:487991pubmed:year1979lld:pubmed
pubmed-article:487991pubmed:articleTitle[Value of pharmacokinetic data during the treatment of psychoses with haloperidol].lld:pubmed
pubmed-article:487991pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:487991pubmed:publicationTypeEnglish Abstractlld:pubmed